Study: 17% of HCV patients have contraindication to therapy

01/28/2013 | Medscape (free registration)

A study found 17.3% of patients with chronic hepatitis C had a contraindication to pegylated interferon and ribavirin therapy, but most were treatable or transient. Bipolar disorders, anemia and pregnancy were the most common contraindications, according to researchers from State University of New York in Buffalo. Those with contraindications tended to be white, younger, female, unmarried and covered by public insurance.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC